BR0108732A - Composição farmacêutica para a prevenção e tratamento da progressão da fibrose e cirrose hepática, seu uso e método para a prevenção e tratamento da fibrose e cirrose hepática - Google Patents

Composição farmacêutica para a prevenção e tratamento da progressão da fibrose e cirrose hepática, seu uso e método para a prevenção e tratamento da fibrose e cirrose hepática

Info

Publication number
BR0108732A
BR0108732A BR0108732-0A BR0108732A BR0108732A BR 0108732 A BR0108732 A BR 0108732A BR 0108732 A BR0108732 A BR 0108732A BR 0108732 A BR0108732 A BR 0108732A
Authority
BR
Brazil
Prior art keywords
prevention
treatment
fibrosis
liver cirrhosis
pharmaceutical composition
Prior art date
Application number
BR0108732-0A
Other languages
English (en)
Inventor
Keon-Wook Kang
Sang-Geon Kim
Original Assignee
Sang-Geon Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sang-Geon Kim filed Critical Sang-Geon Kim
Publication of BR0108732A publication Critical patent/BR0108732A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Abstract

"COMPOSIçãO FARMACêUTICA PARA A PREVENçãO E TRATAMENTO DA PROGRESSãO DA FIBROSE E CIRROSE HEPáTICA, SEU USO E MéTODO PARA A PREVENçãO E TRATAMENTO DA FIBROSE E CIRROSE HEPáTICA". A presente invenção proporciona uma composição farmacêutica que compreende 5-(2-pirazinil)-4-metil-1,2-ditiol-3-tiona (oltipraz) e dimetil-4,4'-dimetoxi-5,6,5',6'-dimetileno-dioxibifenil-2,2'-dicarboxilato (DDB) como os componentes principais. A relação de oltipraz e DDB da referida composição é preferivelmente de 25:0-25, mais preferivelmente de 5:0,1-5, particularmente preferivelmente de 5:1. As formulações de oltipraz/DDB de acordo com a presente invenção apresentam efeitos surpreendentemente bons sobre o tratamento e a prevenção da fibrose e cirrose hepática e são drogas seguras que possuem baixa toxicidade no organismo humano.
BR0108732-0A 2000-03-02 2001-03-02 Composição farmacêutica para a prevenção e tratamento da progressão da fibrose e cirrose hepática, seu uso e método para a prevenção e tratamento da fibrose e cirrose hepática BR0108732A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20000010540 2000-03-02
PCT/KR2001/000320 WO2001064215A1 (en) 2000-03-02 2001-03-02 Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis

Publications (1)

Publication Number Publication Date
BR0108732A true BR0108732A (pt) 2002-12-17

Family

ID=36776473

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108732-0A BR0108732A (pt) 2000-03-02 2001-03-02 Composição farmacêutica para a prevenção e tratamento da progressão da fibrose e cirrose hepática, seu uso e método para a prevenção e tratamento da fibrose e cirrose hepática

Country Status (10)

Country Link
EP (1) EP1263435B1 (pt)
JP (1) JP4226246B2 (pt)
CN (1) CN1218698C (pt)
AT (1) ATE332693T1 (pt)
AU (1) AU2001237768A1 (pt)
BR (1) BR0108732A (pt)
DE (1) DE60121426T2 (pt)
ES (1) ES2267722T3 (pt)
RU (1) RU2250768C2 (pt)
WO (1) WO2001064215A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030067935A (ko) * 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
KR100604261B1 (ko) * 2004-10-11 2006-07-28 재단법인서울대학교산학협력재단 신규4,5,6,7-테트라히드로-[1,2]디티올로[4,3-ｃ]피리딘-3-티온계 화합물
CA2651623A1 (en) 2006-05-11 2007-11-22 Patrick T. Prendergast Compositions and methods for modulating the immune system

Also Published As

Publication number Publication date
JP2004538239A (ja) 2004-12-24
JP4226246B2 (ja) 2009-02-18
ES2267722T3 (es) 2007-03-16
DE60121426T2 (de) 2007-02-22
EP1263435A4 (en) 2004-08-11
RU2002126216A (ru) 2004-03-20
EP1263435A1 (en) 2002-12-11
AU2001237768A1 (en) 2001-09-12
CN1218698C (zh) 2005-09-14
DE60121426D1 (de) 2006-08-24
EP1263435B1 (en) 2006-07-12
RU2250768C2 (ru) 2005-04-27
CN1407891A (zh) 2003-04-02
ATE332693T1 (de) 2006-08-15
WO2001064215A1 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
ATE234634T1 (de) Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff
MY129406A (en) Taste masked liquid pharmaceutical compositions
HUP0302980A3 (en) Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moeties as inhibitors of protein junkinases and pharmaceutical compositions containing them
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
BR0314354A (pt) Formação para gentes lipofìlicos
BRPI0513455A (pt) formulação para mascaramento de sabor compreendendo o fármaco em uma forma de dissolução retardada e/ou ciclodextrina em uma forma de dissolução melhorada
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
GB2334446B (en) Aqueous compositions compromising a lipid and a lanolin-derived surfactant,and their use
BG106155A (en) Novel derivatives and analogues of galanthamin
MY131488A (en) Low dose liquid entecavir formulations and use
WO2005065639A3 (en) Novel pharmaceutical compositions
DE50115451D1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
CA2473202A1 (en) Pharmaceutical composition for regeneration of cirrhotic liver
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient
BR0108732A (pt) Composição farmacêutica para a prevenção e tratamento da progressão da fibrose e cirrose hepática, seu uso e método para a prevenção e tratamento da fibrose e cirrose hepática
CA2385755A1 (en) Prevention of colorectal cancer
ITMI20022549A1 (it) Composizione quaternaria comprendente come sostanza attiva la propolis.
ATE238034T1 (de) Geschmacksmaskierung schlecht schmeckender formulierungen
FR2817257B1 (fr) Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
SE0203817D0 (sv) New composition
MEP39708A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements